Verastem has entered into a one-year research collaboration with Eisai for the next-generation of small molecule Wnt inhibitors. The collaboration aims to develop analogs for VS-507, a proprietary formulation of salinomycin. The resulting compounds will be tested in Verastem’s Wnt signaling and cancer stem cell assays. Verastem will own the analogs that are generated. Eisai will be eligible to receive royalties on commercial sales of identified products. During the term of the agreement, Eisai h...